Nebivolol for improving endothelial dysfunction in cardiac syndrome-x;  Is it ready for clinical use?

Alireza Fatahian

doi:10.22122/arya.v15i6.1971

Vol 15, No 6 (2019):292-293

Nebivolol for improving endothelial dysfunction in cardiac syndrome-x; Is it ready for clinical use?

Alireza Fatahian

DOI: http://dx.doi.org/10.22122/arya.v15i6.1971

Abstract

This article does not have an abstract

Full Text:

PDF

References

Agrawal S, Mehta PK, Bairey Merz CN. Cardiac Syndrome X: Update. Heart Fail Clin 2016; 12(1): 141-56.

Fongemie J, Felix-Getzik E. A review of nebivolol pharmacology and clinical evidence. Drugs 2015; 75(12): 1349-71.

Gao Y, Vanhoutte PM. Nebivolol: An endothelium-friendly selective beta1-adrenoceptor blocker. J Cardiovasc Pharmacol 2012; 59(1): 16-21.

Sen N, Tavil Y, Erdamar H, Yazici HU, Cakir E, Akgul EO, et al. Nebivolol therapy improves endothelial function and increases exercise tolerance in patients with cardiac syndrome X. Anadolu Kardiyol Derg 2009; 9(5): 371-9.

Kayaalti F, Kalay N, Basar E, Mavili E, Duran M, Ozdogru I, et al. Effects of nebivolol therapy on endothelial functions in cardiac syndrome X. Heart Vessels 2010; 25(2): 92-6.

Erdamar H, Sen N, Tavil Y, Yazici HU, Turfan M, Poyraz F, et al. The effect of nebivolol treatment on oxidative stress and antioxidant status in patients with cardiac syndrome-X. Coron Artery Dis 2009; 20(3): 238-4.

Refbacks

There are currently no refbacks.

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.